Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Dossier - 26/03/2012 Diagram showing how proteins (cyan) can enclose a nanoparticle (green) that can bind on the cell membrane to receptors (blue), for example, in the same way free proteins.

    Nanobiotechnology

    What is nanobiotechnology what is the difference between nanotechnology and nanobiotechnology and where and what nanobiotechnological research is being carried out in Germany and more particularly in Baden-Württemberg and which applications is it aimed at?

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/nanobiotechnology
  • Article - 01/07/2019 Mikroschwimmer_-_Bild_1.jpg

    Microswimmers for guided drug delivery

    Medicines should act as quickly as possible and ideally only at the site of disease. However, this may be difficult when the medicines are taken up via the digestive tract or the blood system. Researchers at the Max Planck Institute for Intelligent Systems in Stuttgart have now developed a biohybrid microrobot consisting of red blood cells and bacteria that can be loaded with active ingredients.

    https://www.gesundheitsindustrie-bw.de/en/article/news/microswimmers-guided-drug-delivery
  • Press release - 18/11/2021

    Overcoming resistance to treatment for breast, bowel, and pancreatic cancer

    As cancer progresses, the tumor cells continually change, ultimately resulting in a tumor consisting of a large number of different cell clones with different characteristics. This is referred to as "tumor heterogeneity". In many cases, the cancer cells become resistant to the treatments available.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/overcoming-resistance-treatment-breast-bowel-and-pancreatic-cancer
  • Press release - 05/01/2024

    Prostate cancer: Newly-developed inhibitor shows massive potential

    More than 65,000 men fall ill with prostate cancer each year in Germany. Twelve thousand of them develop a treatment-resistant form which eventually ends in death. Now, a team of researchers from the Medical Faculty at the University of Freiburg has developed an active substance that might in future represent a new treatment option.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/prostate-cancer-newly-developed-inhibitor-shows-massive-potential
  • Press release - 15/01/2025

    Similarities discovered between vascular calcification and bone growth

    University of Tübingen research team observes biochemical process in living cells – indications of new approach to preventing heart attacks and strokes

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/similarities-discovered-between-vascular-calcification-and-bone-growth
  • Press release - 22/05/2025

    Six Clusters of Excellence for the University of Tübingen

    Tübingen achieves remarkable success and has good chance of maintaining its University of Excellence title – Top research in three areas to be sustained from other sources of support.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/six-clusters-excellence-university-tubingen
  • Press release - 13/10/2021

    Tackling the collateral damage from antibiotics

    EMBL scientists pave the way for reducing the harmful side effects antibiotics have on gut bacteria. Antibiotics help us to treat bacterial infections and save millions of lives each year. But they can also harm the helpful microbes residing in our gut, weakening one of our body’s first lines of defence against pathogens and compromising the multiple beneficial effects our microbiota has for our health.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tackling-collateral-damage-antibiotics
  • Press release - 19/03/2021

    New single-cell analysis of leucemic stem cells

    A new method allows stem cells and cancer stem cells to be studied at the single cell level and the resulting cell clones to be traced directly. Studying thousands of individual cells in parallel, the researchers combined the analysis of the genomic cancer mutations with the associated expression profiles.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-single-cell-analysis-leucemic-stem-cells
  • Press release - 21/04/2023

    New research building for engineering life-inspired molecular systems

    Heidelberg University is to acquire a research building to develop innovative engineering science strategies and technologies on the basis of life-inspired molecular systems. The German Science and Humanities Council has now expressed its backing for the idea with an outstanding rating. This recommendation is the crucial precondition for a new building on the university campus Im Neuenheimer Feld.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-research-building-engineering-life-inspired-molecular-systems
  • Press release - 05/06/2023

    New findings about human metabolic processes

    Researchers at the Faculty of Medicine at the University of Freiburg have gained significant new insights into metabolic processes in the kidney. The scientists from the Institute of Genetic Epidemiology at the Medical Center - University of Freiburg measured tiny molecules, so-called metabolites, which occur in blood and urine and reflect our metabolism, in samples from more than 5,000 study participants.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-findings-about-human-metabolic-processes
  • Stem cell research - 14/03/2024 Image of red and blue coloured, round structures.

    Using organoids to gain a better clinical understanding of pancreatic cancer

    Prof. Dr. Alexander Kleger carries out translational research at Ulm University Hospital to gain a better understanding of pancreatic ductal adenocarcinoma (PDAC) and develop individualised treatments. He and his team are using organoid models and stem cell-based systems and have succeeded in simultaneously cultivating all three main cell types of the pancreas from pluripotent stem cells.

    https://www.gesundheitsindustrie-bw.de/en/article/news/using-organoids-gain-better-clinical-understanding-pancreatic-cancer
  • Press release - 03/07/2024

    CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities

    CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced a significant strategic restructuring to focus its resources on high-value mRNA projects in oncology and other select areas of substantial unmet medical need.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-initiates-strategic-restructuring-align-resources-focus-high-value-mrna-pipeline-opportunities
  • Press release - 26/08/2024

    Synthetic Immunology: Approaching a Turning Point in the Treatment and Prevention of Disease

    Synthetic immunology is the topic of an article in the “Perspectives” section of the journal “Nature Nanotechnology”. Herein, Heidelberg researchers describe a so-called bottom-up approach that uses the toolbox of nanotechnology and synthetic biology to construct systems from molecular building blocks and specifically equip them with immune functions.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/synthetic-immunology-approaching-turning-point-treatment-and-prevention-disease
  • Press release - 28/02/2025

    Early Excellence in Science Award für Ivana Winkler

    The Bayer Foundation's Early Excellence in Science Award 2024 in the category of Data Science goes to Ivana Winkler of the German Cancer Research Center (DKFZ). Winkler's work uncovered the unexpected effect of female reproductive capacity: the constantly recurring remodeling of the organs of the female reproductive tract during the sexual cycle leads to fibrosis and chronic inflammation over the years.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/early-excellence-science-award-fuer-ivana-winkler
  • Press release - 06/03/2025

    New insights into the cellular mechanism of action of psilocybin

    A recent study by the Hector Institute for Translational Brain Research at the CIMH provides the first cellular insights into how psilocin promotes the growth and networking of human nerve cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-insights-cellular-mechanism-action-psilocybin
  • Press release - 03/07/2025

    Focus on Muscle Metabolism: Sex Differences in Sport and Obesity

    The skeletal muscles of men and women process glucose and fats in different ways. A study provides the first comprehensive molecular analysis of these differences. The results possibly give an explanation why metabolic diseases such as diabetes manifest differently in women and men – and why they respond differently to physical activity.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/focus-muscle-metabolism-sex-differences-sport-and-obesity
  • Press release - 23/09/2025

    Not all ALK fusions act the same: Variants influence treatment success in lung cancer

    About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until now, clinicians have treated all patients with these fusions the same way. However, new research led by scientists from the German Cancer Research Center (DKFZ) and Stanford University shows that not all fusion variants behave alike.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/not-all-alk-fusions-act-same-variants-influence-treatment-success-lung-cancer
  • Press release - 10/10/2025

    Acidic tumor environment promotes survival and growth of cancer cells

    Tumors are not a comfortable place to live: oxygen deficiency, nutrient scarcity, and the accumulation of sometimes harmful metabolic products constantly stress cancer cells. A research team from the DKFZ and the IMP in Vienna has now discovered that the acidic pH value in tumor tissue is a decisive factor in how pancreatic cancer cells adapt their energy metabolism in order to survive under these adverse conditions.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/acidic-tumor-environment-promotes-survival-and-growth-cancer-cells
  • Press release - 24/11/2025

    Shield against metastases and genetically protected CAR-T cells: Double honor for Mirco Julian Friedrich

    Physician and cancer researcher Mirco Julian Friedrich from the German Cancer Research Center (DKFZ), the stem cell research institute HI-STEM*, and Heidelberg University Hospital (UKHD) has received two awards for two independent research projects: his novel approach to preventing liver metastases and his research on T cells, which he modifies to better protect them from attacks by natural killer cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/shield-against-metastases-and-genetically-protected-car-t-cells-double-honor-mirco-julian-friedrich
  • Press release - 21/05/2025

    How aging changes the blood system in humans and mice

    The reservoir of blood stem cells shrinks with age. It becomes increasingly dominated by stem cells that produce immune cells associated with chronic inflammation. Almost all of the 60-year-olds studied show this change. The new discovery could help explain the chronic inflammation that occurs with age and makes us more susceptible to disease. It could also help identify early warning signs of unhealthy aging processes.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-aging-changes-blood-system-humans-and-mice
  • Article - 14/01/2021 Sven-Diederichs_Teaser.jpg

    Newly discovered RNA as growth driver in liver cancer

    Non-coding RNA (ncRNAs) molecules that do not encode proteins have many different functions, and some are associated with certain diseases. Prof. Dr. Sven Diederichs from the German Consortium for Translational Cancer Research and the German Cancer Research Center in Heidelberg has been conducting research into these molecules at the Freiburg University Medical Centre and discovered a ncRNA that regulates cell proliferation in cancer cells.

    https://www.gesundheitsindustrie-bw.de/en/article/news/newly-discovered-rna-growth-driver-liver-cancer
  • Gene regulation as a starting point for cancer therapies - 02/12/2021 Schematische Darstellung der verschiedenen Stadien der Genexpression. Nukleinsäurestränge sind durch farbige Linien, Proteine durch farbige Ellipsen und die Methylierung durch kleine Kreise dargestellt.

    New investigation method for deciphering complex epigenetic networks

    The development and maintenance of uncontrolled cell division in tumours is often due to the unbalanced, complex interplay of regulatory epigenetic networks. Researchers at the Institute of Biochemistry and Technical Biochemistry in Stuttgart have developed a new screening system to identify essential components that can serve as targets for anticancer drugs.

    https://www.gesundheitsindustrie-bw.de/en/article/news/new-investigation-method-deciphering-complex-epigenetic-networks
  • Press release - 06/09/2022

    Biointelligent sensor for measuring viral activity

    Today, genome editing is almost as easy as programming software. However, the generation of viral vectors as initial material is still associated with many expensive and error-prone handling procedures. Viruses are generated via complex biological processes that have to be optimised virus-specifically in order to produce high-quality therapeutics. A new method is needed that simplifies and optimises these processes.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/Biointelligent-sensor-for-measuring-viral-activity
  • Press release - 19/12/2024

    Antibody that neutralizes inhibitory factors involved in nerve regeneration leads to enhanced motor function after acute spinal cord injury

    Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers at 13 clinics in Germany, Switzerland, the Czech Republic and Spain have investigated this with promising results. For the first time, it was possible to identify patient groups that displayed a clinically relevant treatment effect. A follow-up study will start in December 2024.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/antibody-neutralizes-inhibitory-factors-involved-nerve-regeneration-leads-enhanced-motor-function-after-acute-spinal-cord-injury
  • Press release - 17/05/2021

    New findings in genome research

    The working group around Dr. Philipp Rathert at the Institute for Biochemistry and Technical Biochemistry investigates the regulation of epigenetic networks of certain cancers and ways of treating them. The working group published its new findings in April.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-findings-genome-research

Page 9 / 12

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2026
Website address: https://www.gesundheitsindustrie-bw.de/en/search